Marshall Wace
STOK icon

Marshall Wace’s Stoke Therapeutics STOK Stock Holding History

Marshall Wace’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-768,287
Closed -$18.1M – 3463
2025
Q3 		$18.1M Sell
768,287
-1,532,267
-67% -$26.3M 0.02% 697
2025
Q2 		$26.1M Buy
2,300,554
+168,771
+8% +$1.6M 0.03% 491
2025
Q1 		$14.2M Buy
2,131,783
+1,180,351
+124% +$11M 0.02% 637
2024
Q4 		$10.5M Sell
951,432
-719,301
-43% -$8.84M 0.01% 782
2024
Q3 		$20.5M Buy
1,670,733
+509,696
+44% +$7.22M 0.03% 501
2024
Q2 		$15.7M Buy
1,161,037
+982,451
+550% +$13.3M 0.02% 572
2024
Q1 		$2.41M Buy
+178,586
New +$1.08M ﹤0.01% 1273
2023
Q4 		– Sell
-48,001
Closed -$189K – 2596
2023
Q3 		$189K Buy
+48,001
New +$316K ﹤0.01% 1983
2022
Q4 		– Sell
-20,617
Closed -$265K – 3400
2022
Q3 		$265K Buy
+20,617
New +$329K ﹤0.01% 2995
2022
Q2 		– Sell
-17,237
Closed -$362K – 3827
2022
Q1 		$362K Sell
17,237
-25,164
-59% -$504K ﹤0.01% 2910
2021
Q4 		$1.02M Buy
+42,401
New +$1.01M ﹤0.01% 2467

Other funds holding STOK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's STOK Position: Q4 2025 in Review

Marshall Wace sold out of Stoke Therapeutics (STOK) in Q4 2025, closing a stake of 768,287 shares — an estimated $18.1M sold.

Marshall Wace first reported a position in STOK in Q4 2021 and held it in 11 quarters. The position peaked at $26.1M in Q2 2025. 183 funds tracked by Wall St. Rank hold STOK as of Q4 2025.

  • Marshall Wace reported no remaining Stoke Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Marshall Wace sold 768,287 Stoke Therapeutics shares in Q4 2025, an estimated $18.1M.
  • Marshall Wace first reported a position in Stoke Therapeutics in Q4 2021 and held it in 11 quarters.
  • Marshall Wace's Stoke Therapeutics position peaked at $26.1M in Q2 2025.
  • 183 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2025.

Based on Marshall Wace's 13F filing for Q4 2025, filed 13 Feb 2026.